Recent Updates
Recently added Catalysts

Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400

Phase 2

Dry Eye | Small molecule | Ophthalmology |Abbott Laboratories|Last Updated: Feb 3, 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment110

FDA Designations

No designations recorded

Clinical trial landscape

Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400 · 1 trial · 1 indication

Phase 2 1
NCT00607776Artificial Tears Study in Mild to Moderate Dry Eye PatientsDry Eye
COMPLETED110 Analytics
PHASE2COMPLETED
Artificial Tears Study in Mild to Moderate Dry Eye Patients
Dry Eye
NCT00607776110
Unlock trial analytics

Study Endpoints

Primary Endpoints

Subjective ocular comfort
1 Month

Secondary Endpoints

Vision quality
1 Month
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
1ACTIVE_COMPARATORSystane
2EXPERIMENTALBlink tears

Interventions

NameTypeDescription
(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400DRUGDrops
SystaneDRUGDrops
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Mild to moderate dry eye * over 18 Exclusion Criteria: * No concurrent ocular disease or meds

Unlock Eligibility Criteria